A Quick Look At The Long-Acting Opioid REMS
You may also be interested in...
Opioid REMS: Sponsors Share Implementation, But Also Give Up Some Control
Now that FDA has unveiled what it expects in a Risk Evaluation and Mitigation Strategy for long-acting and extended-release opioids, sponsors will be scrambling to write the REMS for their individual products and put together the shared components and implementation system envisioned by the agency.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.